Zielgerichtete Systemtherapie beim operablen Lungenkarzinom

Zusammenfassung

Das nicht kleinzellige Lungenkarzinom (NSCLC) fällt durch hohe Rezidivraten in den Frühstadien auf. In einer deutschen Kohorte lag das rezidivfreie Überleben nach 5 Jahren bei 62% (Stadium IA1), 40,7% (Stadium IIA) und 28% (Stadium IIIA). Neben dem perioperativen Einsatz von Immuncheckpointinhibitoren drängt auch die zielgerichtete Tumortherapie als Innovation aus dem palliativen Setting in die frühen Stadien. Von besonderer Relevanz ist der Einsatz des EGFR-Inhibitors Osimertinib (EGFR: Epidermal Growth Factor Receptor), für den eine Verbesserung des Gesamtüberlebens in der adjuvanten Situation gezeigt wurde. In dieser praxisorientierten Übersichtarbeit beschreiben wir kurz den aktuellen Stand der adjuvanten zielgerichteten Therapie und der dazugehörigen Testung und geben einen Ausblick auf weitere Entwicklungen.

Abstract

Non-small cell lung cancer (NSCLC) is characterized by high recurrence rates in the early stages. In a German cohort, recurrence-free survival after 5 years was 62% (stage IA1), 40.7% (stage IIA) and 28% (stage IIIA). In addition to the perioperative use of immune checkpoint inhibitors, targeted tumor therapy is also making inroads as an innovation from the palliative setting into the early stages. Of particular relevance is the use of the EGFR inhibitor osimertinib, which has been shown to improve overall survival in the adjuvant setting. In this practice-oriented review, we briefly describe the current status of adjuvant targeted therapy and the associated testing and provide an outlook on further developments.

Schlüsselwörter

NSCLC - Lungenkarzinom - multimodal - Osimertininb - ADAURA - FLAURA

Keywords

NSCLC - ADAURA - Osimertininb - FLAURA

Publication History

Received: 06 May 2024

Accepted after revision: 25 June 2024

Article published online:
13 August 2024

• Literatur

• 1 van Schil PE. Surgery for non-small cell lung cancer. Lung Cancer 2001; 34 (Suppl. 2) S127-S132
• 2 de Koning HJ, van der Aalst CM, de Jong PA. et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 2020; 382: 503-513
• 3 Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615-622
• 4 Hattori A, Suzuki K, Takamochi K. et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial. Lancet Respir Med 2024; 12: 105-116
• 5 Taber S, Pfannschmidt J. Validation of the 8th lung cancer TNM classification and clinical staging system in a German cohort of surgically resected patients. Innov Surg Sci 2020; 5: 1-9
• 6 Lou F, Sima CS, Rusch VW. et al. Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer. Ann Thorac Surg 2014; 98: 1755-1760
• 7 Pignon JP, Tribodet H, Scagliotti GV. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-3559
• 8 Hill W, Lim EL, Weeden CE. et al. Lung adenocarcinoma promotion by air pollutants. Nature 2023; 616: 159-167
• 9 Auliac JB, Thomas PA, Bylicki O. et al. Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study). Ther Adv Med Oncol 2024; 16
• 10 Soria JC, Ohe Y, Vansteenkiste J. et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378: 113-125
• 11 Tsuboi M, Herbst RS, John T. et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med 2023; 389: 137-147
• 12 Wu YL, Tsuboi M, He J. et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2020; 383: 1711-1723
• 13 Herbst RS, Wu YL, John T. et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol 2023; 41: 1830-1840
• 14 Wu YL, Dziadziuszko R, Ahn JS. et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2024; 390: 1265-1276
• 15 Goldman J, Besse B, Wu Y. et al. P01.01 LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC. J Thorac Oncol 2021; 16(10 Suppl): S975-S976
• 16 Lopez-Castro R, Garcia-Pena T, Mielgo-Rubio X. et al. Targeting molecular alterations in non-small-cell lung cancer: what’s next?. Per Med 2022; 19: 341-359
• 17 Zhong WZ, Yan HH, Chen KN. et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal Transduct Target Ther 2023; 8: 76
• 18 Leonetti A, Minari R, Boni L. et al. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial. Clin Lung Cancer 2021; 22: 473-477